Cargando…
Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive–compulsive disorder: a systematic review and meta-analysis of randomized clinical trials
Obsessive–compulsive disorder (OCD) is the fourth most common mental disorder, and selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of its pharmacological treatment. About 40–60% of the cases are treatment-refractory, and this makes searching for second-line treatment necessary. 5...
Autores principales: | Eissazade, Negin, Mosavari, Hesam, Eghdami, Shayan, Boroon, Mahsa, Ashrafi, Faria, Shalbafan, Mohammadreza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682036/ https://www.ncbi.nlm.nih.gov/pubmed/38012263 http://dx.doi.org/10.1038/s41598-023-47931-x |
Ejemplares similares
-
Investigation of a group of Iranian theater artists' mental health and attitude toward patients with mental disorders
por: Eissazade, Negin, et al.
Publicado: (2022) -
Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs)
por: Nikzad, Faezeh, et al.
Publicado: (2021) -
Safety and Efficacy of Drug Holidays for Women with Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) Other than Fluoxetine: An Open-Label Randomized Clinical Trial
por: Lalegani, Elham, et al.
Publicado: (2023) -
Effects of Celecoxib Adjunct to Selective Serotonin Reuptake Inhibitors on Obsessive-Compulsive Disorder
por: Shahini, Najmeh, et al.
Publicado: (2021) -
Phylogenetic analyses of 5-hydroxytryptamine 3 (5-HT(3)) receptors in Metazoa
por: Rao, Santosh T. R. B., et al.
Publicado: (2023)